
1. Adv Exp Med Biol. 2017;959:231-243. doi: 10.1007/978-3-319-55780-9_21.

Gene Therapy in Tyrosinemia: Potential and Pitfalls.

Carter S(1), Doyon Y(2).

Author information: 
(1)Centre Hospitalier Universitaire de Québec Research Center and Faculty of
Medicine, Centre de recherche du CHU de Québec - Université Laval 2705, boulevard
Laurier, T-3-67, Québec, QC, G1V 4G2, Canada.
(2)Centre Hospitalier Universitaire de Québec Research Center and Faculty of
Medicine, Centre de recherche du CHU de Québec - Université Laval 2705, boulevard
Laurier, T-3-67, Québec, QC, G1V 4G2, Canada.
Yannick.Doyon@crchudequebec.ulaval.ca.

In this chapter, we intend to review gene therapy concepts applied to the
potential treatment of tyrosinemia for parents and pediatricians. Therefore, our 
main objective is to give general informations in a comprehensible manner.
Considering the nature of tyrosinemia and the current state of technology, a
particular focus will be put on strategies using viral delivery of DNA to the
liver. In light of the recent development of the CRISPR technology and the
revival of promises for previously unavailable therapeutical tools, the present
chapter aims at presenting up to date facts and potential pitfalls towards an
application for metabolic diseases, in particular tyrosinemia.

DOI: 10.1007/978-3-319-55780-9_21 
PMID: 28755200  [Indexed for MEDLINE]

